Background: Chronic obstructive pulmonary disease (COPD) is a
Introduction
Chronic obstructivepulmonary disease (COPD) is a disease characterized by a progressive airflow limitation and recurrent acute exacerbations associated with an inflammatory response in lungs to the chronic inhalation of noxious particles and gases [1] .
Exacerbations observed during the course of the disease are a major cause of morbidity and mortality. They have an impact on quality of life in patients with COPD, leading to hospitalizations to a considerable extent [2] .
A review of COPD epidemiology indicates that according to the World Health Organization (WHO) dataabout 600 million people suffer from COPD all over the world, with 2.3 million people dying each year because of COPD [3] . Furthermore, COPD is currently the fourth leading cause of death among all others, and it is projected to be the third by 2020 [4] Genetic and environmental factors, inflammation and oxidative stress contribute to development of COPD. Some inflammatory mediators such as monocyte-macrophages, CD8 T-lymphocytes, neutrophils, eosinophils and interleukin (IL)-8, leukotriene B4 (LTB4), tumor necrosisfactor (TNF)-α are involved in COPD inflammation.
The main source of pathological findings in COPD is the destructive and structural changes caused by inflammatory products. Any acute exacerbation of COPD leads to increased airway inflammation, and thus increased release of inflammatory mediators [5, 6] .
C-reactive protein (CRP), the first acute phase reactant discovered, is detected in serum as early as four hours after the damage.
Early and quick diagnosis of COPD exacerbationis very important, particularly in prevention of mortality. Therefore, CRP and procalcitonin are mainly used as biomarkers to determine COPD exacerbation and response. Recently, a new biomarker called suPAR (Soluble form of the urokinase-type plasminogen activator receptor) with significantly elevated levels in diseases such as sepsis and bacteremia has been identified [7] [8] [9] .
Soluble urokinase-type plasminogen activator receptor (suPAR) is released from the membranebound plasminogen activator, and is positively correlated with the activation of immune system. Numerous studies on various infections, inflammatory diseases and cancer have shown increased systemic levels of suPAR [10] [11] [12] [13] [14] . However, the new biological marker, suPAR has not been studied in demonstrating COPD exacerbation. remarkable decrease was seen in the suPAR levels obtained before and after the management of exacerbations (p= 0.001 and p= 0.06 respectively).
Conclusion:
These results support the idea that suPAR, a novel biomarker, might be an important indicator if verified with further prospective studies in evaluating COPD exacerbations and treatment response like CRP used for decades. The aim of present study was to determine if suPAR, as a new biological marker, is as sensitive as CRP in the evaluation of COPD exacerbations and response.
Material Methods
The COPD patients who presented to the Chest Diseases Clinic between October 2012 and April 2013 were divided into 3 groups; those with stable COPD [SCOPD] (n= 54), pre-treatment acute exacerbation COPD [AECOPD] (n= 53), and posttreatment AECOPD (n= 52). AECOPD and posttreatment AECOPD group consisted of the same patients; Yet, we had an exodus and thus one patient less. Presence of one or more symptoms such as increased amount of sputum, purulence, shortness of breath, chest tightness, and wheezing was considered an acute exacerbation [15, 16] . For SCOPD, patients were required not to have any acute exacerbation symptoms at least in a fourweek period. We excluded those who were younger than 40 years, and pregnant, had a non-COPD disease such as asthma-bronchiectasis-tuberculosis, malignancy (pulmonary and non-pulmonary), chronic renal failure associated with increased serum level of CRP, chronic liver failure, collagen tissue disease, and cardiac diseases including vasculitis. All patients provided a detailed medical history including their smoking status and duration of disease; and their physical examination findings, chest X-rays and grades of dyspnea (according to the ATS dyspnea score) were evaluated;and respiratory function tests, and arterial blood gas parameters were assessed.
Measurement of serum CRP level;Peripheral venous blood samples were obtained using EDTAcontaining blood collection tubes. Then, the samples were centrifuged at 3000 rpm for 5 min to separate the plasma. The plasma was stored at -80 o C in a deep freezer before performing the CRP assays. CRP (Cardio Phase CRP, Siemens Healthcare Daignostics Products GmbH, Hamburg, Germany) assays were performed by using a fully-automated nephelometric assay system (BN II Seimens Healthcare Diagnostics Inc. Tarrytown, NY, USA). The reference range for CRP was 0.00-5.00 mg/L in healthy individuals depending on the assay method used.
The plasma samples of patients were stored at 80 o C in a deep freezer for measurement of suPAR levels like CRP. For suPAR assays, a micro ELISA reactive (Receptor (PLAUR/uPAR) ELISA Kit, Hangzhou Eastbiopharm Co. Ltd. Hangzhou, PRC) and a micro plate reader (Biotek ELx 800, BioTek Instrumentations, Inc, Winooski, VT, USA) were used.
The study protocol was approved by the local ethics committee. A written informed consent was obtained from all subjects.
Statistical Analyses
All statistical analyses were performed using SPSS statistical package (version 15 for Windows, SPSS; Chicago, Ill., USA). Descriptive analyses were performed for all variables. The association between two quantitative variables was evaluated with Pearson's correlation coefficient. The results were expressed as means and standard deviations for quantitative variables, and as frequencies for categorical findings. To compare means of two independent groups, student's t test was used, while nonparametric data were analyzed with the MannWhitney U test. The Kruskal-Wallis test was used to compare nonparametric data of several groups. To identify the differences between the aforementioned markers, we performed an unadjusted and adjusted regression analysis and a logistic regression analysis. The level of statistical significance was taken as p<0.05.
Results
The patients with COPD were divided into 3 groups for evaluations: The mean age of groups were SCOPD (62.12±9.26 years), pre-treatment AECOPD (66.13±10.34 years), and post-treatment AECOPD (66.30±10.34 years). The demographic characteristics of groups are shown in Table 1 .
All patients were male. CRP and suPAR were measured in all groups.
The suPAR levels for SCOPD was 1.21±0.59, for AECOPD was 1.28±0.52, and post-treatment AECOPD 1.02±0.41 (Table 2-3) . Accordingly, in the AECOPD group the suPAR level was elevated during exacerbations compared to SCOPD; yet without a statistical significance (p= 0,49). In addition, post-treatment suPAR levels were lower than pre-treatment in the AECOPD group. However the difference was not statistically significant (p= 0,06).
CRP levels of SCOPD group was 5.02±6.31, of pre-treatment AECOPD 54.82±56.63, and posttreatment AECOPD 5.93±5.20. The CRP levels of pre-treatment AECOPD levels were higher than both groups and statistically significant (p<0,05) (Table 2-3) .
The area under curve (AUC) value for CRP was 0.88, (p= 0.001) and cut off value was 7,67. Additionally, sensitivity was 84.9% and specifity was 85.0%. On the other hand, the AUC value for su-PAR was 0.621 (p= 0.01) (Figure 1) .
According to Spearman's correlation analysis, the correlation between CRP and suPAR was r= 0.147 (p= 0.06). Therefore, it was concluded that suPAR was not as sensitive as CRP as a biomarker of exacerbations in patients with COPD (Figure 2) . 
Discussion
In the present study, plasma suPAR levels of AECO-PD patients were higher than the SCOPD group; yet this difference is not statistically signifcant. Likewise pre-treatment plasma suPAR levels of AECOPD patients was higher than post-treatment AECOPD; yet without statistically significant. Backes et al. showed that diagnostic value of suPAR is low in demonstrating inflammation, which is also consistent with our findings [17] . Regarding the suPAR levels of SCOPD patients throghout an inflammation there is, acording to our best knowledge, only one report in the current literature [18] . In that study, the plasma su-PAR levels of the SCOPD patients were signicantly higher than that of the healthy controls indicating the these findings might reflect the inlammatory process in SCOPD.
Additionally, Gustafsson et al. compared the suPAR levels in patients with severe sepsis with other inflammatory markers, and showed that suPAR can be used in predicting severity and mortality of sepsis [19] . Similarly, Donadello et al.indicated that suPAR can be used as prognostic biomaker in sepsis [20] . More than 150 biological markers have been studied in patients with sepsis, however most of them are not routinely used in daily practice [21] .
In the present study, CRP levels of both SCOPD and post-treatment AECOPD were lower compared to pre-treatment AECOPD in line with the reduced inflammation. This difference in the CRP levels of both groups were statistically significant.
In line with the present study, Hurst et al. showed that CRP is the most practical and best known biomarker in detecting COPD exacerbations [22] . This is the first pilot study on suPAR concentrations in patients with SCOPD and AECOPD.
Limitations of the study: The limitations of our study is the lack of a comparison with healthy controls, limited patient series, and that all participants were male. In conclusion, we believe that the new biomarker, suPAR is not as sensitive as CRP in demonstrating COPD exacerbations, and its use as a marker of exacerbation may be limited in patients with COPD. Future studies with larger patient series and with a control group consisting of healthy patients may reflect the inflammatory process in AECOPD patients based on plasma suPAR levels. Yet, before it can be used like CRP further clinical studies including more patients to evaluate suPAR in patients with COPD are needed.
